VYNE Therapeutics

Q1 FY2026 EarningsVYNE Therapeutics completed its merger with Yarrow Bioscience (now trading as YARW), securing $200M in private financing to fund operations into 2028. The company initiated a Phase 2a/2b trial for lead candidate YB-101 (anti-TSHR antibody) for Graves’ disease and thyroid eye disease, with Phase 2a data expected in 2H 2027. Following a 1-for-50 reverse stock split and the merger, the combined entity has 2.8M shares outstanding (33.6M fully-diluted) and previously distributed a $17.3M special cash dividend.